SunTrust Banks Weighs in on Catalyst Pharmaceutical Partners Inc.’s FY2020 Earnings (CPRX)
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) – Equities researchers at SunTrust Banks dropped their FY2020 EPS estimates for Catalyst Pharmaceutical Partners in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash now expects that the firm will post earnings of $0.13 per share for the year, down from their prior forecast of $0.16.
CPRX has been the topic of a number of other research reports. Roth Capital reiterated a “buy” rating and issued a $2.50 target price on shares of Catalyst Pharmaceutical Partners in a report on Friday, October 14th. Piper Jaffray Cos. upgraded Catalyst Pharmaceutical Partners from a “neutral” rating to an “overweight” rating and set a $4.00 target price on the stock in a report on Wednesday, October 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Catalyst Pharmaceutical Partners currently has a consensus rating of “Buy” and a consensus price target of $3.38.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded down 0.965% during mid-day trading on Monday, hitting $1.129. 529,180 shares of the stock traded hands. The stock has a 50-day moving average of $1.16 and a 200 day moving average of $0.89. Catalyst Pharmaceutical Partners has a 1-year low of $0.51 and a 1-year high of $3.00. The firm’s market cap is $93.56 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last released its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01.
A number of institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new position in Catalyst Pharmaceutical Partners during the second quarter worth approximately $440,000. Oxford Asset Management increased its position in Catalyst Pharmaceutical Partners by 3.5% in the second quarter. Oxford Asset Management now owns 180,721 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 6,140 shares in the last quarter. DRW Securities LLC purchased a new position in Catalyst Pharmaceutical Partners during the second quarter worth approximately $168,000. Baker BROS. Advisors LP purchased a new position in Catalyst Pharmaceutical Partners during the third quarter worth approximately $5,561,000. Finally, Northern Trust Corp increased its position in Catalyst Pharmaceutical Partners by 41.2% in the third quarter. Northern Trust Corp now owns 127,584 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 37,217 shares in the last quarter. Hedge funds and other institutional investors own 30.31% of the company’s stock.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Stock Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related stocks with our FREE daily email newsletter.